2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12H.03 Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in NSCLC Patients with EGFR Mutation

EP.12H.03 Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in NSCLC Patients with EGFR Mutation

Back to course

Pdf Summary

The Korean EGFR Registry is a comprehensive multicenter observational cohort study designed to evaluate the treatment outcomes and clinical characteristics of non-small cell lung cancer (NSCLC) patients with EGFR mutations in Korea. This study, led by Chang Dong Yeo, involves enrolling 2,000 NSCLC patients from forty university hospitals across Korea, encompassing both retrospective and prospective cohorts. The primary focus is on understanding the disease-free survival for patients receiving definitive therapy and progression-free survival for those undergoing palliative therapy, categorized by their cancer stages.<br /><br />The project aims to gather extensive data on patient demographics, smoking history, quality of life, pathologic information, and treatment results, with follow-up ongoing until December 2026. This includes reviewing diagnostic methods for EGFR mutations and analyzing treatment outcomes based on different modalities, alongside examining metastatic patterns in these patients.<br /><br />A significant aspect of the study is the investigation of a new third-generation EGFR tyrosine kinase inhibitor, lazertinib, evaluating its safety and effectiveness in both first- and second-line treatments. By exploring these dimensions, the research intends to generate valuable insights into the epidemiology, risk factors, and progression of EGFR-mutated NSCLC in Korea, contributing to more personalized and effective treatment strategies.<br /><br />Ultimately, the study aims to enhance understanding of the complex dynamics surrounding EGFR-mutated NSCLC, providing a substantial database that can support future clinical recommendations and treatment pathways for cancer care in Korea and potentially beyond.

Asset Subtitle

Chang Dong Yeo

Meta Tag

Speaker Chang Dong Yeo

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Korean EGFR Registry

non-small cell lung cancer

NSCLC

EGFR mutations

Chang Dong Yeo

lazertinib

tyrosine kinase inhibitor

treatment outcomes

metastatic patterns

personalized treatment